Azaya Therapeutics Receives FDA Authorization to Start Phase I Cancer Trial

Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product ATI-1123, a novel and improved formulation of Taxotere (docetaxel), a leading chemotherapy drug.

Related Posts

Comments are closed.